TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23373662
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of opportunistic infections prophylaxis
Study: 6138084
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oxazepam
Study: 21321086
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg once daily (qd)
Study: 21321086
Drug: Motesanib 75
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 75 mg twice daily (b.i.d.) 5 days on/2 days off
Study: 21321086
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg every 3 weeks (q3w)
Study: 15933353
Drug: Co-prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-prescription of heroin (inhalable or injectable) over 12 months
Study: 15933353
Drug: Methadone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone alone (maximum 150 mg a day)
Study: 12131942
Drug: Intramuscular diclofenac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac, 75 mg associated with intravenous physiological saline, 10 ml
Study: 2468183
Drug: Single-agent ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent ifosfamide
Study: 2468183
Drug: BIP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIP combination (ifosfamide, cisplatin, and bleomycin)
Study: 871634
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg prazosin with 100 mmol sodium intake
Study: 871634
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prazosin with 100 mmol sodium intake
Study: 871634
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg prazosin with 250 mmol sodium intake
Study: 871634
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prazosin with 250 mmol sodium intake
Study: 11425770
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Aspirin and Warfarin)
Study: 11425770
Drug: Control (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Placebo + Warfarin)
Study: 11425770
Drug: Control (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Placebo + Aspirin)
Study: 30021096
Drug: l-glutamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-glutamine (0.3 g/kg per dose, administered twice daily)
Study: 26718379
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (940-nm gallium-aluminum-arsenic diode laser, 200 mW, 20 seconds at 3 points on buccal mucosa)
Study: 26718379
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy (laser not turned on)
Study: 22581038
Drug: Patient-specific carbohydrate
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific carbohydrate absorption factor
Study: 22581038
Drug: BG-dependent variable
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-dependent variable insulin appearance rate
Study: 17275636
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing by nomogram
Study: 17275636
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing by house staff
Study: 12851279
Drug: Tifacogin (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tifacogin (0.025 mg/kg per hour for 96 hours, n = 880)
Study: 10536644
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at incremental doses from 0.010 to 0.030 microgram kg‐1 min‐1
Study: 30137664
Drug: Concizumab (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concizumab (0.25, 0.5, and 0.8 mg kg‐1, once every 4 days)
Study: 30137664
Drug: Concizumab (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concizumab (highest dose cohort)
Study: 23148736
Drug: Doripenem (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem (7-day course, 1g as a four-hour infusion every eight hours)
Study: 23148736
Drug: Imipenem-cilastatin (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (10-day course, 1g as a one-hour infusion every eight hours)
Study: 15857205
Drug: Spirulina (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (2,000 mg/day)
Study: 15857205
Drug: Spirulina (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (1,000 mg/day)
Study: 10466547
Drug: DTPw-HBV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HBV combination vaccine containing 10 microg of HBsAg
Study: 10466547
Drug: DTPw-HBV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HBV combination vaccine containing 5 microg of HBsAg
Study: 10466547
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTPw and HBV (10 microg of HBsAg)
Study: 7838634
Drug: Glucose-ORS (G-ORS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-ORS (G-ORS)
Study: 7838634
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (RF-ORS, G-ORS, RD-ORS)
Study: 2244843
Drug: Ticlopidine (antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (antiplatelet agent)
Study: 30836195
Drug: PEMF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF therapy (immediate post-surgery for 6 hours, then 3 hours for the next 6 days, and 1.5 hours for days 8-13)
Study: 30836195
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (no extra treatment)
Study: 23947742
Drug: PEMF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF therapy
Study: 22521233
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (flexible dose of one of five antipsychotic medications)
Study: 10102948
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 2 weeks
Study: 10102948
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 4 weeks
Study: 7766739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 4 weeks
Study: 7480102
Drug: Sugar-coated tablet
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablet formulation containing 50 mg standardized horse chestnut seed extract
Study: 7480102
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation in capsule form containing 50 mg standardized horse chestnut seed extract
Study: 7389382
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin 3-times daily
Study: 7389382
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline daily
Study: 26002889
Drug: Oxygen (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (8 L/min)
Study: 22708612
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (observation and immediate imitation of common daily hand and arm actions)
Study: 22708612
Drug: Usual rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual rehabilitation without any trial-related treatment
Study: 15366525
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup therapy
Study: 3310569
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 160 mg/day)
Study: 1704983
Drug: Felodipine plus
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine plus metoprolol 10 + 100 mg (FM)
Study: 1704983
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg (F)
Study: 1704983
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg (M)
Study: 168121
Drug: Intravenous adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenocorticotropic hormone (ACTH)
Study: 31618446
Drug: Sertraline and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and/or mirtazapine
Study: 27600280
Drug: Paclitaxel-carboplatin-bevacizumab (PCB)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel-carboplatin-bevacizumab (PCB) with nitroglycerin patches
Study: 27600280
Drug: Paclitaxel-carboplatin-bevacizumab (PCB)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel-carboplatin-bevacizumab (PCB) without nitroglycerin patches (control)
Study: 24419513
Drug: Once-daily (QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (QD) administration of intra-venous (IV) BU
Study: 24419513
Drug: Four-times-daily (4QD)
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-times-daily (4QD) administration of intra-venous (IV) BU
Study: 17880350
Drug: Reduced appraisals
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced appraisals of past harm from baseline to end of treatment
Study: 17880350
Drug: Increased harm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased harm appraisals from baseline to end of treatment
Study: 17880350
Drug: Higher treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher treatment intensity and 12-step affiliation
Study: 9806528
Drug: Bladder and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder and rectal volumes
Study: 8548939
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment in TBII negative patients (Group A)
Study: 8548939
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment in TBII positive patients (Group B)
Study: 2173354
Drug: Long-term diazepam
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term diazepam treatment
Study: 2173354
Drug: Acute i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute i.v. diazepam administration
Study: 27882605
Drug: 6 mg/kgBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kgBM caffeine (CAF)
Study: 23998234
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of docosahexaenoic acid
Study: 21430660
Drug: Tocilizumab infusion
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab infusion
Study: 18180893
Drug: Dobell's solution
Normalized name: Dobell's Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobell's solution (Control)
Study: 14745658
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 microg) twice daily
Study: 11207464
Drug: Lidocaine 50
Normalized name: lidocaine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 50 mg with adrenaline
Study: 11207464
Drug: Lidocaine 100
Normalized name: lidocaine 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 100 mg with adrenaline
Study: 9435413
Drug: Active buccal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active buccal tablet containing 10 mg testosterone
Study: 9435413
Drug: Buccal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal placebo tablet containing 3 mg pseudoephedrine HCl for taste matching
Study: 8608205
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with chlormadinone acetate (CMA)
Study: 8608205
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with acetazolamide (ACET)
Study: 15616073
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg
Study: 31468673
Drug: Biyeom-go treatment
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biyeom-go treatment >3 times daily for a total of 4 weeks
Study: 29908675
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder (30 g) and dark chocolate (50 g) daily for 1 week
Study: 22120130
Drug: omega-3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 group (6 g/d fish oil; n = 91)
Study: 18416220
Drug: Zero-balanced ultrafiltration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero-balanced ultrafiltration (ZBUF) (50 ml/kg) and conventional ultrafiltration (CUF)
Study: 8073431
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50-150 mg for five consecutive days in each treatment cycle
Study: 2800898
Drug: 10% cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% cyclosporin gel
Study: 1090222
Drug: Paraldehyde (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraldehyde (10 ml rectally every 30 minutes)
Study: 1090222
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg then 5 mg intravenously every 5 minutes)
Study: 8609945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate (7.5 to 17.5 mg per week), sulfasalazine (500 mg twice daily), and hydroxychloroquine (200 mg twice daily)
Study: 8609945
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (7.5 to 17.5 mg per week)
Study: 8609945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice daily)
Study: 3802705
Drug: Nitrendipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (mean dose 32 mg/day)
Study: 3802705
Drug: Acebutolol (414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (414 mg/day)
Study: 3802705
Drug: Nitrendipine and
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine and Acebutolol (both treatments)
Study: 20413522
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) intravenously at weeks 0, 2, 6, and 14
Study: 16217977
Drug: 5-day telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day telithromycin (800 mg once daily)
Study: 16217977
Drug: 10-day amoxicillin-clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day amoxicillin-clavulanate (500/125 mg 3 times daily)
Study: 16217977
Drug: 10-day cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day cefuroxime axetil (250 mg twice daily)
Study: 1693714
Drug: Felodipine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (2.5, 5, and 10 mg b.i.d. for 2 weeks each)
Study: 27951450
Drug: Standard-interval chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-interval chemotherapy
Study: 26154930
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell infusion (1.0 x 10^7 cells/vessel)
Study: 26154930
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell infusion (3.0 x 10^7 cells/vessel)
Study: 20090145
Drug: Odontic Microsystem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odontic Microsystem treatment developed by R. Voll and R. Dale
Study: 20090145
Drug: Complex treatment
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex treatment for patients with inner organ pathology
Study: 16446328
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan (40 mg/m2/d MTD without cefixime; 60 mg/m2/d MTD with cefixime)
Study: 16446328
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg/d beginning 5 days before irinotecan and continuing throughout the course)
Study: 16446328
Drug: Cefixime with
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime with oral irinotecan
Study: 16446328
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan without cefixime
Study: 16446328
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan with cefixime
Study: 11423921
Drug: Red Wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Wine Supplementation (240 ml/day)
Study: 9243749
Drug: Hep B-3
Normalized name: amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hep B-3 vaccine containing both preS1- and preS2-derived proteins in addition to hepatitis B surface antigen
Study: 7961239
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of naloxone HCl (60 micrograms)
Study: 7961239
Drug: Systemic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic infusion of naloxone (4 mg)
Study: 3591419
Drug: Low dosage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage, titrated ECT
Study: 27544007
Drug: 24-month dual-antiplatelet
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-month dual-antiplatelet therapy (DAPT)
Study: 27544007
Drug: 6-month dual-antiplatelet
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month dual-antiplatelet therapy (DAPT)
Study: 24352823
Drug: I-ONE therapy
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-ONE therapy administered postoperatively four hours per day for 60 days
Study: 24352823
Drug: I-ONE therapy
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-ONE therapy
Study: 20444849
Drug: Trastuzumab in
Normalized name: trastuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab in combination with capecitabine
Study: 16625329
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (Treatment Arm A)
Study: 16625329
Drug: Surgery, then
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm B)
Study: 16625329
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C (Treatment Arm D)
Study: 16625329
Drug: Surgery, then
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm C)
Study: 12794547
Drug: Two-dose intrapartum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose intrapartum neonatal nevirapine regimen
Study: 10845685
Drug: Self-emulsifying vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-emulsifying vitamin E preparation
Study: 10845685
Drug: Self-emulsifying vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-emulsifying vitamin E preparation and Natopherol
Study: 1640362
Drug: Experimental formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulation of theophylline with 70% drum-dried corn starch (DDCS-70)
Study: 1640362
Drug: Theo-dur (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-dur (reference sustained-release formulation)
Study: 1640362
Drug: Experimental formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulation with 50% starch
Study: 27782892
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (5×10^9 CFU B. lactis B94)
Study: 27782892
Drug: Synbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic treatment (5×10^9 CFU B. lactis B94 and 900 mg inulin)
Study: 27782892
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment (900 mg inulin)
Study: 25251432
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous (3 mg/kg q 24 hr)
Study: 25251432
Drug: High-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intermittent (three doses of 45 mg/kg q 6 hr repeated q 1 wk)
Study: 25251432
Drug: Both low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both low-dose continuous and high-dose intermittent
Study: 22133661
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring (daily dose of 15 mcg ethinylestradiol/120 mcg etonogestrel)
Study: 20663495
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (OC) for 6 to 8 weeks before assisted reproduction treatment (ART)
Study: 20663495
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment with oral contraception (OC)